Search results for: 'top test'

The global pharmaceutical industry strives to build an inclusive partner ecosystem that integrates technology, data, and regulatory standardization-enabled innovation into clinical trial delivery. This transformation aims to reduce the burden on investigators and sites while improving the efficiency and accuracy of adverse event (AE) tracking. Driv...

Owing to constant developments and challenges in the life sciences industry, stakeholders must continue to be adaptable, innovative, and competitive to thrive. Industry leaders must reconsider their strategic positions annually by understanding the main forces behind the transformation, including potential, challenges, and drivers. This analysis e...

The pharmaceutical and biotechnology industries are entering a transformative era in 2025, shaped by a convergence of scientific innovation, regulatory evolution, and market pressures. One of the key imperatives is the continued advancement of therapeutics and drug approvals, as breakthrough treatments, particularly in personalized medicine, promis...

The SCOPE Summit 2026, held in Orlando, Florida, from February 2 to 5, 2026, highlighted the dominance of small- to mid-segment companies and specialized CROs focusing on specific therapy areas or aspects of clinical trials, such as bioanalysis. With more than 4,000 attendees, 630 speakers, and 300 exhibitors, SCOPE 2026 reinforced its position as ...

As the industry continues to innovate across novel small- and large-molecule therapies, including RNA-targeted small molecules, cell and gene therapies, and mRNA therapies, pharma sponsors increasingly rely on partners for technology access, database generation and analysis, and preclinical and clinical research.These disruptions continue to drive ...

Europe’s life sciences sector is approaching a defining inflection point in 2026, as major regulatory and policy reforms converge to reshape pharma, diagnostics, life sciences IT, biotechnology, and the bioeconomy. Together, these frameworks open clear growth pathways across the value chain: the Clinical Trials Regulation (CTR) and European Health ...

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) delivers strategic insights into breakthrough innovations shaping the future of healthcare, life sciences, and precision medicine. It highlights AI-driven platforms, advanced biologics, and digital health solutions that address critical challenges in accessibili...

The study on the "Global Biologics Contract Development & Manufacturing Organizations (CDMO) Market: Companies-to-Action" presents an overview of the global biologics development and manufacturing landscape with an emphasis on the seven leading CDMOs in the market. The study highlights the shifting focus and investments of bio-pharma companies towa...